Evidence map›Paper›PMID 30251061›Full record

Observational studyEuropean journal of clinical pharmacology2019

Dose reduction, oral application, and order of intake to preserve aspirin antiplatelet effects in dipyrone co-medicated chronic artery disease patients.

Lisa Dannenberg, Tobias Petzold, Alina Achilles, David Naguib, Saif Zako, Carolin Helten, René M'Pembele, Philipp Mourikis, Yanina Podsvyadek, Maria Grandoch and 5 more

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in European journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Metamizole: Indications and Risks.Deutsches Arzteblatt international · 2026
    Review
  4. Observational
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Lisa DannenbergDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany. lisa.dannenberg@med.uni-duesseldorf.de.
Tobias PetzoldDepartment of Cardiology, LMU München, Munich, Germany.
Alina AchillesDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
David NaguibDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Saif ZakoDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Carolin HeltenDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
René M'PembeleDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Philipp MourikisDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Yanina PodsvyadekInstitute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, Düsseldorf, Germany.
Maria GrandochInstitute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, Düsseldorf, Germany.
Bodo LevkauWest German Heart and Vascular Center, University Hospital Essen, University of Duisburg-Essen, Institute of Pathophysiology, Essen, Germany.
Tobias ZeusDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Malte KelmDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Thomas HohlfeldInstitute for Pharmacology and Clinical Pharmacology, Heinrich Heine University, Düsseldorf, Germany.
Amin PolzinDivision of Cardiology, Pulmonology, and Vascular Medicine, Heinrich Heine University Medical Center Dusseldorf, Düsseldorf, Germany.
Heinrich Heine University Düsseldorf · DEDüsseldorf University Hospital · DELudwig-Maximilians-Universität München · DEWest German Heart and Vascular Center Essen · DE

Funding

Medical Faculty of the Heinrich-Heine-University Düsseldorf No. 16-2014Medical Faculty of the Heinrich-Heine-University Düsseldorf No 46-2016
6 · The paper itself

Abstract

backgroundDipyrone comedication in aspirin-treated patients is associated with impaired pharmacodynamic response to aspirin (high on-treatment platelet reactivity [HTPR]). Additionally, in small observational studies, an association with impaired outcome has been described. In this uncontrolled, hypothesis-generating study, we aimed to investigate strategies to prevent this drug-drug interaction in patients with coronary artery disease (CAD).

methodsWe analyzed pharmacodynamic response to aspirin in 80 dipyrone co-medicated CAD patients. Aspirin antiplatelet effects were measured using arachidonic acid (AA)-induced light-transmission aggregometry (LTA). Platelet reactivity was associated with daily dose, administration form, and frequency. Additionally, we conducted a time-series analysis in patients with HTPR to aspirin with re-evaluation of pharmacodynamic response to aspirin after 5 days.

resultsPatients' mean age was 75.5 ± 9.8 years. Forty-three (54%) were male, 22 (27.5%) obese, and 38 (47.5%) diabetics. Baseline characteristics, cardiovascular risk factors, comorbidities, comedication, or laboratory parameters did not differ between patients with or without HTPR. HTPR to aspirin occurred in 34 out of 80 patients (42.5%). The incidence of HTPR was associated with dipyrone daily dose (< 1 g/day: HTPR 20% vs. > 3 g/day: HTPR 50%, p > 0.0001) and form of administration (i.v. 87.5% vs. oral 37.5%; p < 0.0001). A strict order of intake (aspirin 30 min prior to dipyrone) restored aspirin antiplatelet effects in all patients (HTPR before 100% vs. HTPR after 0%, p = 0.0002).

conclusionThis study shows that dipyrone should be used with caution in aspirin-treated patients. If dipyrone seems indispensable, the lowest effective dose and a strict order of intake seem favorable.

Indexed as

Administration, OralAgedAged, 80 and overAnti-Inflammatory Agents, Non-SteroidalArachidonic AcidAspirinCoronary Artery DiseaseDipyroneDose-Response Relationship, DrugDrug Administration ScheduleDrug InteractionsFemaleHumansMaleMiddle AgedPlatelet Aggregation InhibitorsAnti-Inflammatory Agents, Non-SteroidalArachidonic AcidAspirinDipyronePlatelet Aggregation InhibitorsAggregationAspirinComedicationDipyronePlatelet activationPlatelet inhibition

Identifiers

PMID30251061
OpenAlexW2892809417

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.